Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc.

MRVINYSE / NASDAQHealthcareSmall cap

$6.98-$0.21 (-2.9%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
-14.1x
EV / EBITDA
-13.5x
Revenue
$185.7M
Net margin
-70.4%
ROCE
-17.7%

+104.1% over the last year

Maravai LifeSciences Holdings, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-3.1%
3M
-15.8%
6M
+57.6%
1Y
+104.1%
5Y
-81.4%

52-week range

Day change -$0.21 (-2.9%) from $7.19 to $6.98 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MRVI, bought on each weekday since 2021.

News & filings

What Maravai LifeSciences Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 131 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 26.3% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.

Read moreShow less

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Sector
Healthcare
Shares outstanding
145.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
-14.1x
P/B
8.7x
EV / EBITDA
-13.5x
EV / Sales
10.7x
P/S
9.9x
52-week high
$9.00
52-week low
$2.83

Profitability

Operating margin
-69.2%
Net margin
-70.4%
EBITDA margin
-79.4%
ROE
-61.6%
ROCE
-17.7%
ROIC
-31.6%
ROA
-17.0%
Asset turnover
0.24

Growth

Revenue
$185.7M
Revenue growth, 1Y
-28.3%
Revenue CAGR, 3Y
-40.5%
Net profit growth, 1Y
-9.7%
Free cash flow
-$70.7M

Solvency

Current ratio
6.60
Debt / Equity
1.72
Debt / Assets
0.47
CFO / Net profit
0.44
Cash / Market cap
11.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$185.7M
Cost of revenue$151.8M
Gross profit$34.0M
Operating expenses$162.5M
Research and development$17.4M
Selling, general and administrative$145.1M
Operating income-$128.5M
Interest and other-$106.4M
Pretax income-$235.0M
Tax and other-$104.2M
Net income-$130.8M

Revenue and net profit

Revenue fell 28.3% in FY2025; net profit is the dashed line.

Maravai LifeSciences Holdings, Inc. revenue and net profit by fiscal year
Maravai LifeSciences Holdings, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$883.0M$220.2M
FY2023$288.9M-$119.0M
FY2024$259.2M-$144.8M
FY2025$185.7M-$130.8M

Cash flows

FY2025: -$57.6M from operations, -$70.7M free after investment (dashed).

Maravai LifeSciences Holdings, Inc. operating and free cash flow by fiscal year
Maravai LifeSciences Holdings, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$536.0M$518.9M
FY2023$126.2M$60.7M
FY2024$7.5M-$22.2M
FY2025-$57.6M-$70.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$185.7M-28.3%1Y
EBITDA
-$147.5M
Net profit
-$130.8M
Cash from operations
-$57.6M-871.2%1Y
Free cash flow
-$70.7M
Revenue CAGR, 3Y
-40.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$185.7M-$147.5M-$130.8M-$70.7M-61.6%-28.3%-9.7%

Monthly returns

Month-by-month returns of MRVI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$770.6M
Liabilities$397.9M
Equity$372.7M
Paid-in capital$199.2M
Retained earnings$10.1M
Minority interest$160.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MRVI highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Maravai LifeSciences Holdings, Inc. (this company)10.7x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Maravai LifeSciences Holdings, Inc.MRVIthis company$1.8B-14.1x8.7x-61.6%-13.5x
Astrana Health, Inc.ASTH$1.9B83.5x2.4x2.9%18.7x
Stoke Therapeutics, Inc.STOK$1.9B-272.5x5.3x-2.0%-95.4x
Pulse Biosciences, Inc.PLSE$1.9B-25.6x23.1x-90.2%-23.6x
Zymeworks Inc.ZYME$1.8B-22.8x6.9x-30.2%-22.4x
Pediatrix Medical Group, Inc.MD$1.8B11.1x2.1x19.1%7.6x
Viridian Therapeutics, Inc.VRDN$1.8B-5.3x3.1x-58.1%-4.9x
Vericel CorporationVCEL$1.8B110.3x5.1x4.7%60.3x
ANI Pharmaceuticals, Inc.ANIP$1.8B23.0x3.3x14.5%10.3x
Peer median—2.9x4.2x0.5%1.3x

Year-to-date ROI

MRVI since 1 January, against earlier years.

Historical volatility

MRVI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Maravai LifeSciences Holdings, Inc. operating margin by fiscal year
Maravai LifeSciences Holdings, Inc. operating margin by fiscal year
DateOperating margin
FY202264.1%
FY2023-9.9%
FY2024-28.0%
FY2025-69.2%
LineFY2025
Cost of revenueCost Of Revenue$151.8M
Gross profitGross Profit$34.0M
Operating expensesOperating Expense$162.5M
Research and developmentResearch And Development$17.4M
Selling, general and administrativeSelling General And Administration$145.1M
Total expensesTotal Expenses$314.3M
Pretax incomePretax Income-$235.0M

Learn while you research

Academy chapters picked for Maravai LifeSciences Holdings, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 1.72 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →